Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1080-1086

  Brown, Gregory Thomas ^a   Kleiner, David E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Histology; Liver biopsy; Steatohepatitis; Steatosis

Indexed keywords

BARIATRIC SURGERY; DISEASE SEVERITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIPODYSTROPHY; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER HISTOLOGY; NATIONAL HEALTH ORGANIZATION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; BIOPSY; COMPLICATION; FATTY LIVER; LIVER; METABOLIC SYNDROME X; PATHOLOGY;

BIOPSY; FATTY LIVER; HUMANS; LIVER; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84954289151     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.11.008     Document Type: Review

References (56)

1. [1] d'Assignies, G., Fontes, G., Kauffmann, C., Latour, M., Gaboury, L., Boulanger, Y., et al. Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and intralipid solutions and correlation to insulin levels. Metabolism 62 (2013), 1850–1857.
2. [2] Adams, L.A., Ratziu, V., Non-alcoholic fatty liver — perhaps not so benign. J Hepatol 62 (2015), 1002–1004.
3. [3] Argo, C.K., Caldwell, S.H., Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 13 (2009), 511–531.
4. [4] Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
5. [5] Karagozian, R., Derdak, Z., Baffy, G., Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63 (2014), 607–617.
6. [6] Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59 (2013), 550–556.
7. [7] McPherson, S., Hardy, T., Henderson, E., Burt, A.D., Day, C.P., Anstee, Q.M., Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
8. [8] Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
9. [9] Malik, S.M., Devera, M.E., Fontes, P., Shaikh, O., Sasatomi, E., Ahmad, J., Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 15 (2009), 1843–1851.
10. [10] Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003), 917–923.
11. [11] Sanyal, A.J., Brunt, E.M., Kleiner, D.E., Kowdley, K.V., Chalasani, N., Lavine, J.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
12. [12] Wree, A., Schlattjan, M., Bechmann, L.P., Claudel, T., Sowa, J.P., Stojakovic, T., et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 63 (2014), 1542–1552.
13. [13] Chalasani, N., Wilson, L., Kleiner, D.E., Cummings, O.W., Brunt, E.M., Unalp, A., et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48 (2008), 829–834.
14. [14] Lefkowitch, J.H., Haythe, J.H., Regent, N., Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol 15 (2002), 699–704.
15. [15] Gadd, V.L., Skoien, R., Powell, E.E., Fagan, K.J., Winterford, C., Horsfall, L., et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 59 (2014), 1393–1405.
16. [16] Brunt, E.M., Kleiner, D.E., Wilson, L.A., Unalp, A., Behling, C.E., Lavine, J.E., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49 (2009), 809–820.
17. [17] Argo, C.K., Northup, P.G., Al-Osaimi, A.M., Caldwell, S.H., Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51 (2009), 371–379.
18. [18] Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
19. [19] Wieckowska, A., Zein, N.N., Yerian, L.M., Lopez, A.R., McCullough, A.J., Feldstein, A.E., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006), 27–33.
20. [20] Feldstein, A.E., Wieckowska, A., Lopez, A.R., Liu, Y.C., Zein, N.N., McCullough, A.J., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50 (2009), 1072–1078.
21. [21] Guy, C.D., Suzuki, A., Burchette, J.L., Brunt, E.M., Abdelmalek, M.F., Cardona, D., et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol 43 (2012), 790–800.
22. [22] Zatloukal, K., French, S.W., Stumptner, C., Strnad, P., Harada, M., Toivola, D.M., et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 313 (2007), 2033–2049.
23. [23] Franke, W.W., Denk, H., Schmid, E., Osborn, M., Weber, K., Ultrastructural, biochemical, and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbriated rods of filaments containing prekeratin-like polypeptides. Lab Invest 40 (1979), 207–220.
24. [24] Zatloukal, K., Stumptner, C., Fuchsbichler, A., Heid, H., Schnoelzer, M., Kenner, L., et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160 (2002), 255–263.
25. [25] Cadrin, M., Marceau, N., French, S.W., Cytokeratin of apparent high molecular weight in livers from griseofulvin-fed mice. J Hepatol 14 (1992), 226–231.
26. [26] Mallory, F.B., Cirrhosis of the Liver. Five different types of lesions from which it may arise. Johns Hopkins Hosp Bull 22 (1911), 69–75.
27. [27] Caldwell, S.H., Lee, V.D., Kleiner, D.E., Al-Osaimi, A.M., Argo, C.K., Northup, P.G., et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 8 (2009), 346–352.
28. [28] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
29. [29] Klion, F.M., Schaffner, F., The ultrastructure of acidophilic “Councilman-like” bodies in the liver. Am J Pathol 48 (1966), 755–767.
30. [30] Wakabayashi, T., Megamitochondria formation — physiology and pathology. J Cell Mol Med 6 (2002), 497–538.
31. [31] Caldwell, S.H., Chang, C.Y., Nakamoto, R.K., Krugner-Higby, L., Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004), 595–617.
32. [32] Matsuhashi, T., Liu, X., Nishizawa, Y., Usukura, J., Wozniak, M., Wakabayashi, T., Mechanism of the formation of megamitochondria in the mouse liver induced by chloramphenicol. Toxicol Lett 86 (1996), 47–54.
33. [33] Pinto, H.C., Baptista, A., Camilo, M.E., Valente, A., Saragoca, A., de Moura, M.C., Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 41 (1996), 172–179.
34. [34] Nelson, J.E., Wilson, L., Brunt, E.M., Yeh, M.M., Kleiner, D.E., Unalp-Arida, A., et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53 (2011), 448–457.
35. [35] Valenti, L., Fracanzani, A.L., Dongiovanni, P., Rovida, S., Rametta, R., Fatta, E., et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 20 (2014), 3002–3010.
36. [36] Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., Bacon, B.R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999), 2467–2474.
37. [37] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
38. [38] Hjelkrem, M., Stauch, C., Shaw, J., Harrison, S.A., Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther 34 (2011), 214–218.
39. [39] Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.L., Basdevant, A., Paradis, V., et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56 (2012), 1751–1759.
40. [40] Schwimmer, J.B., Behling, C., Newbury, R., Deutsch, R., Nievergelt, C., Schork, N.J., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 (2005), 641–649.
41. [41] Nobili, V., Marcellini, M., Devito, R., Ciampalini, P., Piemonte, F., Comparcola, D., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44 (2006), 458–465.
42. [42] Carter-Kent, C., Yerian, L.M., Brunt, E.M., Angulo, P., Kohli, R., Ling, S.C., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 50 (2009), 1113–1120.
43. [43] Patton, H.M., Lavine, J.E., Van Natta, M.L., Schwimmer, J.B., Kleiner, D., Molleston, J., et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology, 135, 2008, e1962.
44. [44] Moretto, M., Kupski, C., Mottin, C.C., Repetto, G., Garcia Toneto, M., Rizzolli, J., et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg 13 (2003), 622–624.
45. [45] Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137 (2009), 532–540.
46. [46] Chavez-Tapia, N.C., Tellez-Avila, F.I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., Uribe, M., Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev, 2010, 10.1002/14651858.CD007340.pub2.
47. [47] Klein, S., Mittendorfer, B., Eagon, J.C., Patterson, B., Grant, L., Feirt, N., et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130 (2006), 1564–1572.
48. [48] Machado, M., Marques-Vidal, P., Cortez-Pinto, H., Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006), 600–606.
49. [49] Kleiner, D.E., Berk, P.D., Hsu, J.Y., Courcoulas, A.P., Flum, D., Khandelwal, S., et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 34 (2014), 98–107.
50. [50] Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388.
51. [51] Odom, J., Zalesin, K.C., Washington, T.L., Miller, W.W., Hakmeh, B., Zaremba, D.L., et al. Behavioral predictors of weight regain after bariatric surgery. Obes Surg 20 (2010), 349–356.
52. [52] Christou, N.V., Look, D., Maclean, L.D., Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 244 (2006), 734–740.
53. [53] Magro, D.O., Geloneze, B., Delfini, R., Pareja, B.C., Callejas, F., Pareja, J.C., Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 18 (2008), 648–651.
54. [54] Garg, A., Acquired and inherited lipodystrophies. N Engl J Med 350 (2004), 1220–1234.
55. [55] Akinci, B., Koseoglu, F.D., Onay, H., Yavuz, S., Altay, C., Simsir, I.Y., et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism 64 (2015), 1086–1095.
56. [56] Safar Zadeh, E., Lungu, A.O., Cochran, E.K., Brown, R.J., Ghany, M.G., Heller, T., et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 59 (2013), 131–137.